We’ve got some late-breaking news to report — plus, it’s been a busy news week overall, and some of our email alerts didn’t go out, due to a programming glitch. Below, here are some recent stories you may have missed.
A tribunal at Queen Mary University of London has decided to disclose the data from the controversial PACE trial, which tested various therapies for chronic fatigue syndrome. For critics of this study, this has been a long-awaited decision.
What’s more, Science is reporting that Sweden’s Central Ethical Review Board has found Paolo Macchiarini guilty of misconduct in a 2014 paper. This comes after years of questions over his work, leading to multiple resignations and investigations. For a primer on the ever-evolving case, see our timeline.
Here are some of our other stories from this week that weren’t emailed to subscribers, due to a programming glitch:
- The Journal of the American College of Cardiology (JACC) has retracted a recently published paper that questioned the effectiveness of a treatment for irregular heartbeat — the last author vehemently objected (even taking his concerns to social media), and implied industry played a role.
- The University of Colorado has revoked the PhD of a former promising student — known once as the “golden boy” — following an investigation that identified multiple instances of misconduct.
- Biologist Alan Levine lost a second paper, and the retraction notice was practically identical to one issued a year earlier.
- A probe found neuroscientists didn’t generate key images in their study in Frontiers in Neuroscience.
- Swiss and French institutions are investigating several papers in molecular biology — the announcement isn’t very informative, but according to Swiss paper NZZ, the researcher in question is not Olivier Voinnet.
- A Spanish lab has admitted to misconduct, and retracted one paper and corrected another.
Like Retraction Watch? Consider making a tax-deductible contribution to support our growth. You can also follow us on Twitter, like us on Facebook, add us to your RSS reader, sign up on our homepage for an email every time there’s a new post, or subscribe to our daily digest. Click here to review our Comments Policy. For a sneak peek at what we’re working on, click here.